JP2016508517A5 - - Google Patents

Download PDF

Info

Publication number
JP2016508517A5
JP2016508517A5 JP2015558127A JP2015558127A JP2016508517A5 JP 2016508517 A5 JP2016508517 A5 JP 2016508517A5 JP 2015558127 A JP2015558127 A JP 2015558127A JP 2015558127 A JP2015558127 A JP 2015558127A JP 2016508517 A5 JP2016508517 A5 JP 2016508517A5
Authority
JP
Japan
Prior art keywords
polypeptide
seq
amino acid
sequence shown
removals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015558127A
Other languages
English (en)
Japanese (ja)
Other versions
JP6480872B2 (ja
JP2016508517A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/016244 external-priority patent/WO2014127120A1/en
Publication of JP2016508517A publication Critical patent/JP2016508517A/ja
Publication of JP2016508517A5 publication Critical patent/JP2016508517A5/ja
Application granted granted Critical
Publication of JP6480872B2 publication Critical patent/JP6480872B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015558127A 2013-02-15 2014-02-13 インスリン分泌性ポリペプチド Expired - Fee Related JP6480872B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361765276P 2013-02-15 2013-02-15
US61/765,276 2013-02-15
PCT/US2014/016244 WO2014127120A1 (en) 2013-02-15 2014-02-13 Insulin secreting polypeptides

Publications (3)

Publication Number Publication Date
JP2016508517A JP2016508517A (ja) 2016-03-22
JP2016508517A5 true JP2016508517A5 (enExample) 2017-03-09
JP6480872B2 JP6480872B2 (ja) 2019-03-13

Family

ID=51354543

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015558127A Expired - Fee Related JP6480872B2 (ja) 2013-02-15 2014-02-13 インスリン分泌性ポリペプチド

Country Status (6)

Country Link
US (2) US9938334B2 (enExample)
EP (1) EP2956160B1 (enExample)
JP (1) JP6480872B2 (enExample)
CN (1) CN105101990B (enExample)
DK (1) DK2956160T3 (enExample)
WO (1) WO2014127120A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014525439A (ja) 2011-08-30 2014-09-29 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ ナトリウム利尿ポリペプチド
WO2013103896A1 (en) 2012-01-06 2013-07-11 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
EP3296746A1 (en) * 2016-09-20 2018-03-21 Université de Bourgogne In vitro method for diagnosing at early stage intestinal ischemia
KR20250150662A (ko) 2022-11-02 2025-10-20 노보 노르디스크 에이/에스 Cnp 화합물
WO2025235379A1 (en) * 2024-05-06 2025-11-13 Mayo Foundation For Medical Education And Research Polypeptides having natriuretic and insulin-secreting actions, and methods for their use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757048A (en) 1985-11-05 1988-07-12 Biotechnology Research Associates J.V. Synthetic analogs of atrial natriuretic peptides
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
CN1331533C (zh) * 1997-02-05 2007-08-15 第一阿斯比奥制药株式会社 心肌肥大性心脏病治疗用药物组合物
US8076288B2 (en) * 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
EA200702419A1 (ru) 2005-05-05 2008-04-28 Кадила Хелзкэр Лимитед Новые соединения как агонисты glp-1
EP1922336B1 (en) 2005-08-11 2012-11-21 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
WO2007030706A1 (en) * 2005-09-08 2007-03-15 New England Medical Center Hospitals, Inc. Fragments of the glucagon-like peptide-i and uses thereof
CA2800389A1 (en) 2006-04-20 2007-11-01 Amgen Inc. Glp-1 compounds
EP2080812A1 (en) * 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
JP5127658B2 (ja) * 2008-10-06 2013-01-23 キヤノン株式会社 通信装置、通信装置の制御方法、コンピュータプログラム及び記憶媒体
SG175411A1 (en) 2009-05-01 2011-12-29 Hoffmann La Roche Insulinotropic peptide synthesis using solid and solution phase combination techniques

Similar Documents

Publication Publication Date Title
RU2017116973A (ru) Способы применения и композиции нейрегулинов для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса
JP2016508517A5 (enExample)
JP2017532343A5 (enExample)
EA202090392A3 (ru) Соединения-коагонисты гип и гпп-1
JP2015518818A5 (enExample)
MX2016013243A (es) Agonistas peptídicos duales de los receptores de glp-1/glucagón derivados de la exendina-4.
JP2016139345A5 (enExample)
JP2012136541A5 (enExample)
WO2016057529A3 (en) Biphasic single-chain insulin analogues
TN2017000271A1 (en) Glucagon derivative having improved stability
JP2013503110A5 (enExample)
JP2013136622A5 (enExample)
JP2012529293A5 (enExample)
JP2018519366A5 (enExample)
NZ726623A (en) Improved peptide pharmaceuticals for insulin resistance
EA033007B1 (ru) ПОЛИПЕПТИД, СОДЕРЖАЩИЙ ЛИПИДИРОВАННЫЙ ГЕТЕРОДИМЕР МУТАНТНЫХ ФРАГМЕНТОВ OspA, СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА И ЕГО ПРИМЕНЕНИЯ
RU2017143580A (ru) Улучшенные последовательности уриказы и способы лечения
JP2016515123A5 (enExample)
EA201592272A1 (ru) ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ ИЗМЕНЕННУЮ АМИНОКИСЛОТНУЮ ПОСЛЕДОВАТЕЛЬНОСТЬ g3p БАКТЕРИОФАГА С ПОНИЖЕННОЙ ИММУНОГЕННОСТЬЮ
WO2015168488A3 (en) Islet amyloid polypeptides with improved solubility
RU2017126212A (ru) Композиция
PH12018501319A1 (en) Insulinotropic peptide derivative with modified n-terminal charge
JP2017517561A5 (enExample)
MX2017000878A (es) Peptidos marinos y nucleotidos de pescado, composiciones y sus usos para reducir la glucosa en la sangre.
JP2016222601A5 (enExample)